Clinical Observation of Chronic Hepatitis C Treated by Pegylated Interferon Alpha-2a Plus Ribavirin
- VernacularTitle:聚乙二醇干扰素α-2a联合利巴韦林治疗慢性丙型肝炎的临床观察
- Author:
Yongrui YANG
;
Hui LI
;
Ling SHEN
- Publication Type:Journal Article
- Keywords:
Chronic hepatitis C;
Pegylated interferon alpha-2a;
Ribavirin;
Efficacy;
Safety
- From:
Journal of Kunming Medical University
2014;(2):100-101,104
- CountryChina
- Language:Chinese
-
Abstract:
Objective To observe the efficacy and safety of pegylated interferon apha-2a combined with ribavirin in the treatment of chronic hepatitis C.Methods One hundred and six patients with chronic hepatitis C were divided into 2 groups randomly.Patients in the observation group were treated with pegylated interferon alpha-2a,and patients in the control group were treated with interferon alpha-1b.All patients were given ribavirin according to the weight,and the treatment course was 48 weeks.HCV-RNA was tested before treatment,4 weeks, 12weeks and 24 weeks after the start of treatment,end of treatment,24 weeks after the end of treatment.The adverse reactions were also observed.Results In the observation group,the rapid virological response (RVR) was 77.4%,the complete early virological response (cEVR) was 83.0%,the end treatment virological response (ETVR) was 90.6%, the sustained virological response (SVR) of 24 weeks after the end of treatment was 84.9%.and these rates were significantly higher than the control group.All patients received the whole course of treatment.Condusion Treatment of chronic hepatitis C with pegylated interferon apha-2a combined with ribavirin is effective and safe.
